PROCEPT BioRobotics is a urology robotics franchise trying to prove that Aquablation demand is real after a year of borrowed handpiece sales. New chief executive Larry Wood spent the first half of the year ending a bulk-order discount program, destocking hospital shelves, and realigning the commercial force. The June quarter is the first print in which handpiece shipments again track procedures rather than outrun them. United States handpiece units sold equaled about 98% of procedures performed. That alignment, not the headline growth rate, is the entire investment debate.
The commercial reset is visible in mix. System placements accelerated while consumable growth lagged as hospitals worked through leftover inventory. United States system revenue rose 32% as HYDROS placements set a company record. Handpiece and consumable revenue grew only 12%, which is the destock still showing up in the mix. Gross margin reached 66%. A one-time tariff refund of $3 million helped that print. Operating expense still outran sales, so the adjusted EBITDA loss widened. The equity is asking whether HYDROS utilization and a cleaner razor-and-blade cadence can convert mid-sixties gross profit into operating leverage before cash burn forces another financing conversation.
Management kept full-year revenue guidance unchanged and narrowed the procedure outlook after the first-half destock. A strengthened American Urological Association recommendation and completed WATER IV enrollment give the franchise two genuine clinical catalysts that do not depend on channel stuffing. Cash and restricted cash still totaled $231 million at mid-year, which buys time but does not buy credibility. The open question is whether second-half procedure volume can close the gap to the reiterated sales range without another round of discounting.